@article {HOEHR2017200,
	title = {Medical Isotope Production at TRIUMF {\textendash} from Imaging to Treatment},
	journal = {Physics Procedia},
	volume = {90},
	year = {2017},
	note = {Conference on the Application of Accelerators in Research and Industry, CAARI 2016, 30 October {\textendash} 4 November 2016, Ft. Worth, TX, USA},
	pages = {200 - 208},
	abstract = {TRIUMF has a long history of medical isotope production. For more than 40 years, the Life Sciences Division at TRIUMF has produced isotopes for Positron Emission Tomography (PET) for the local hospitals. Recently, the division has taken on the challenge to expand the facility{\textquoteright}s isotope repertoire to isotopes for imaging to treatment. At the smallest cyclotron at TRIUMF with energy of 13 MeV, radiometals are being produced in a liquid target which is typically used for PET isotope production. This effort makes radiometals available for early stage research and preclinical trials. At beam energy of 24 MeV, we produce 99mTc from 100Mo with a cyclotron, the most common isotope for Single-Photon-Emission-Computed-Tomography (SPECT) and the most common isotope for nuclear imaging. The use of a cyclotron bypasses the common production route via a nuclear reactor as well as enriched uranium. And finally, at our 500 MeV cyclotron we have demonstrated the production of α emitters useful for targeted alpha therapy. Herein, these efforts are summarized.},
	keywords = {alpha therapy isotopes, PET isotopes, SPECT isotopes, TC-99M},
	issn = {1875-3892},
	doi = {https://doi.org/10.1016/j.phpro.2017.09.059},
	url = {http://www.sciencedirect.com/science/article/pii/S1875389217302183},
	author = {C. Hoehr and F. B{\'e}nard and K. Buckley and J. Crawford and A. Gottberg and V. Hanemaayer and P. Kunz and K. Ladouceur and V. Radchenko and C. Ramogida and A. Robertson and T. Ruth and N. Zacchia and S. Zeisler and P. Schaffer}
}
